Showing 961 - 980 results of 9,305 for search 'significantly ((((((lower decrease) OR (we decrease))) OR (nn decrease))) OR (linear decrease))', query time: 0.46s Refine Results
  1. 961

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

    Published 2025
    “…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”
  2. 962

    Image 1_Lower hippocampal volumes at baseline are associated with higher volume loss in healthy elderly.png by Vivian Schultz (17379235)

    Published 2025
    “…Small, but statistically significant positive correlations were found between baseline hippocampal z-scores and APC of hippocampal volumes over time, indicating that the lower the volume at baseline, the greater the atrophy rate to timepoint two (right hippocampus: r = 0.17, p = 0.01; left hippocampus: r = 0.14, p = 0.03). …”
  3. 963

    Original data2. by Lan Zeng (638254)

    Published 2025
    “…<div><p>Diabetic retinopathy (DR) is a leading cause of blindness. We hypothesised that the long non-coding RNA <i>RP11-502I4.3</i> may be involved in angiogenesis associated with DR. …”
  4. 964

    Original data1. by Lan Zeng (638254)

    Published 2025
    “…<div><p>Diabetic retinopathy (DR) is a leading cause of blindness. We hypothesised that the long non-coding RNA <i>RP11-502I4.3</i> may be involved in angiogenesis associated with DR. …”
  5. 965
  6. 966

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  7. 967

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  8. 968

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  9. 969
  10. 970

    Questionnaire description. by Cristobal Padilla-Fortunatti (21376807)

    Published 2025
    “…<div><p>Background</p><p>During the last decades, intensive care unit (ICU) mortality rates have significantly decreased but this progress has come with unintended consequences for patients and their caregivers. …”
  11. 971
  12. 972

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

    Published 2024
    “…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”
  13. 973
  14. 974

    MXene/Bi<sub>2</sub>O<sub>3</sub> Nanocomposites as Supercapacitors for Portable Electronic Devices by Nanasaheb M. Shinde (8560572)

    Published 2025
    “…2D MXene nanosheets often encounter challenges such as aggregation and restacking, which can significantly decrease their performance in supercapacitor applications. …”
  15. 975
  16. 976
  17. 977
  18. 978
  19. 979
  20. 980